7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial. - Zhou, C.; Xiong, A.; Zhao, J.; Li, W.; Bi, M.; Chen, J.; Li, K.; Miao, L.; Mao, Y.; Wang, D.; Liu, C.; Zeng, A.; et al. (Annals of Oncology, 2022)